Sumitomo Pharma Co Ltd
OTC:SMDPY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sumitomo Pharma Co Ltd
OTC:SMDPY
|
JP |
|
T
|
Troax Group AB (publ)
F:5TOA
|
SE |
|
Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
|
NZ |
|
K
|
Kingfish Company NV
OSE:KING
|
NL |
Wall St Price Targets
SMDPY Price Targets Summary
Sumitomo Pharma Co Ltd
According to Wall Street analysts, the average 1-year price target for
SMDPY is 13.73 USD with a low forecast of 10.37 USD and a high forecast of 18.68 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SMDPY's stock price target?
Price Target
13.73
USD
According to Wall Street analysts, the average 1-year price target for
SMDPY is 13.73 USD with a low forecast of 10.37 USD and a high forecast of 18.68 USD.
What is the Revenue forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
11%
Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 3 years is 11%.
What is the Gross Profit forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
-83%
Over the last 13 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 1 year is -83%.
What is the Pre-Tax Income forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
-4%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is -4%.
What is the Net Income forecast for Sumitomo Pharma Co Ltd?
Projected CAGR
-14%
Over the last 13 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is -14%.